Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene

Aldrin V Gomes, James D. Potter

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Mutations in the cardiac troponin I (CTnI) gene occur in ∼5% of families with familial hypertrophic cardiomyopathy (FHC) and 20 mutations in this gene that cause FHC have now been described. The clinical manifestations of CTnI mutations that cause FHC are diverse, ranging from asymptomatic with high life expectancy to severe heart failure and sudden cardiac death. Most of these FHC mutations in CTnI result in cardiac hypertrophy unlike cardiac troponin T FHC mutations. All CTnI FHC mutations investigated in vitro affect the physiological function of CTnI, but other factors such as environmental or genetic factors (other genes that may affect the CTnI gene) are likely to be involved in influencing the severity of the phenotype produced by these mutations, since the distribution of hypertrophy among affected individuals varies within and between families. CTnI mutations mainly alter myocardial performance via changes in the Ca2+-sensitivity of force development and in some cases alter the muscle relaxation kinetics due to haemodynamic or physical obstructions of blood flow from the left ventricle.

Original languageEnglish (US)
Pages (from-to)99-114
Number of pages16
JournalMolecular and Cellular Biochemistry
Volume263
Issue number1
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Familial Hypertrophic Cardiomyopathy
Troponin I
Genes
Mutation
Troponin T
Hemodynamics
Muscle Relaxation
Sudden Cardiac Death
Cardiomegaly
Life Expectancy
Muscle
Hypertrophy
Blood
Heart Ventricles
Heart Failure
Kinetics
Phenotype

Keywords

  • Cardiac
  • Familial hypertrophic cardiomyopathy
  • Muscle contraction and calcium
  • Toponin I

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Genetics
  • Cell Biology

Cite this

Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene. / Gomes, Aldrin V; Potter, James D.

In: Molecular and Cellular Biochemistry, Vol. 263, No. 1, 08.2004, p. 99-114.

Research output: Contribution to journalArticle

@article{27f7e8380457497a94e2452edfc65fa7,
title = "Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene",
abstract = "Mutations in the cardiac troponin I (CTnI) gene occur in ∼5{\%} of families with familial hypertrophic cardiomyopathy (FHC) and 20 mutations in this gene that cause FHC have now been described. The clinical manifestations of CTnI mutations that cause FHC are diverse, ranging from asymptomatic with high life expectancy to severe heart failure and sudden cardiac death. Most of these FHC mutations in CTnI result in cardiac hypertrophy unlike cardiac troponin T FHC mutations. All CTnI FHC mutations investigated in vitro affect the physiological function of CTnI, but other factors such as environmental or genetic factors (other genes that may affect the CTnI gene) are likely to be involved in influencing the severity of the phenotype produced by these mutations, since the distribution of hypertrophy among affected individuals varies within and between families. CTnI mutations mainly alter myocardial performance via changes in the Ca2+-sensitivity of force development and in some cases alter the muscle relaxation kinetics due to haemodynamic or physical obstructions of blood flow from the left ventricle.",
keywords = "Cardiac, Familial hypertrophic cardiomyopathy, Muscle contraction and calcium, Toponin I",
author = "Gomes, {Aldrin V} and Potter, {James D.}",
year = "2004",
month = "8",
doi = "10.1023/B:MCBI.0000041852.42291.aa",
language = "English (US)",
volume = "263",
pages = "99--114",
journal = "Molecular and Cellular Biochemistry",
issn = "0300-8177",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene

AU - Gomes, Aldrin V

AU - Potter, James D.

PY - 2004/8

Y1 - 2004/8

N2 - Mutations in the cardiac troponin I (CTnI) gene occur in ∼5% of families with familial hypertrophic cardiomyopathy (FHC) and 20 mutations in this gene that cause FHC have now been described. The clinical manifestations of CTnI mutations that cause FHC are diverse, ranging from asymptomatic with high life expectancy to severe heart failure and sudden cardiac death. Most of these FHC mutations in CTnI result in cardiac hypertrophy unlike cardiac troponin T FHC mutations. All CTnI FHC mutations investigated in vitro affect the physiological function of CTnI, but other factors such as environmental or genetic factors (other genes that may affect the CTnI gene) are likely to be involved in influencing the severity of the phenotype produced by these mutations, since the distribution of hypertrophy among affected individuals varies within and between families. CTnI mutations mainly alter myocardial performance via changes in the Ca2+-sensitivity of force development and in some cases alter the muscle relaxation kinetics due to haemodynamic or physical obstructions of blood flow from the left ventricle.

AB - Mutations in the cardiac troponin I (CTnI) gene occur in ∼5% of families with familial hypertrophic cardiomyopathy (FHC) and 20 mutations in this gene that cause FHC have now been described. The clinical manifestations of CTnI mutations that cause FHC are diverse, ranging from asymptomatic with high life expectancy to severe heart failure and sudden cardiac death. Most of these FHC mutations in CTnI result in cardiac hypertrophy unlike cardiac troponin T FHC mutations. All CTnI FHC mutations investigated in vitro affect the physiological function of CTnI, but other factors such as environmental or genetic factors (other genes that may affect the CTnI gene) are likely to be involved in influencing the severity of the phenotype produced by these mutations, since the distribution of hypertrophy among affected individuals varies within and between families. CTnI mutations mainly alter myocardial performance via changes in the Ca2+-sensitivity of force development and in some cases alter the muscle relaxation kinetics due to haemodynamic or physical obstructions of blood flow from the left ventricle.

KW - Cardiac

KW - Familial hypertrophic cardiomyopathy

KW - Muscle contraction and calcium

KW - Toponin I

UR - http://www.scopus.com/inward/record.url?scp=4544291412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544291412&partnerID=8YFLogxK

U2 - 10.1023/B:MCBI.0000041852.42291.aa

DO - 10.1023/B:MCBI.0000041852.42291.aa

M3 - Article

C2 - 15524171

AN - SCOPUS:4544291412

VL - 263

SP - 99

EP - 114

JO - Molecular and Cellular Biochemistry

JF - Molecular and Cellular Biochemistry

SN - 0300-8177

IS - 1

ER -